Mednax, Inc (NYSE:MD) – Investment analysts at Jefferies Group cut their Q3 2017 earnings per share (EPS) estimates for Mednax in a research note issued on Tuesday. Jefferies Group analyst B. Tanquilut now forecasts that the company will post earnings per share of $0.80 for the quarter, down from their prior forecast of $0.81. Jefferies Group has a “Hold” rating and a $46.00 price target on the stock. Jefferies Group also issued estimates for Mednax’s Q4 2017 earnings at $0.81 EPS, FY2017 earnings at $3.11 EPS and FY2018 earnings at $3.38 EPS.

Mednax (NYSE:MD) last posted its quarterly earnings results on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.81 by $0.04. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The company had revenue of $843.00 million for the quarter, compared to the consensus estimate of $849.49 million. During the same period last year, the firm posted $1.03 EPS. The company’s revenue for the quarter was up 9.2% on a year-over-year basis. ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/11/research-analysts-issue-forecasts-for-mednax-incs-q3-2017-earnings-md.html.

Several other brokerages also recently commented on MD. BidaskClub upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Stephens upgraded shares of Mednax from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $55.00 to $68.00 in a research note on Thursday, June 22nd. Mizuho restated a “neutral” rating and issued a $48.00 target price (down previously from $62.00) on shares of Mednax in a research note on Tuesday, August 1st. Robert W. Baird restated a “hold” rating and issued a $47.00 target price on shares of Mednax in a research note on Sunday, September 3rd. Finally, Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $56.63.

Mednax (NYSE MD) opened at 43.03 on Wednesday. The stock has a 50 day moving average of $43.11 and a 200-day moving average of $53.49. The company has a market capitalization of $3.97 billion, a P/E ratio of 13.70 and a beta of 0.37. Mednax has a 52-week low of $40.78 and a 52-week high of $72.13.

Institutional investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. raised its holdings in shares of Mednax by 3.2% in the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock valued at $125,000 after buying an additional 55 shares during the last quarter. Commonwealth Bank of Australia raised its holdings in shares of Mednax by 15.3% in the second quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock valued at $132,000 after buying an additional 293 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of Mednax by 20.0% in the second quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock valued at $181,000 after buying an additional 500 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. bought a new position in shares of Mednax in the second quarter valued at about $217,000. Finally, QS Investors LLC raised its holdings in shares of Mednax by 0.3% in the second quarter. QS Investors LLC now owns 3,812 shares of the company’s stock valued at $230,000 after buying an additional 12 shares during the last quarter.

In related news, insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.40% of the company’s stock.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.